What are the costs of tigecycline injection generics?

What factors influence the cost of tigecycline injection generics?

Tigecycline generics entered the U.S. market after the reference product's patent and exclusivity periods ended. Multiple manufacturers now offer versions of the 50 mg vial, including Accord Healthcare, Amneal, and Mylan. Prices per vial range widely, from $80 to $450, depending on wholesaler, quantity purchased, and current supply disruptions.

How do tigecycline generic prices compare to the original brand?

The original brand (Tygacil) reached $200–$300 per vial before generics launched. After entry, prices fell roughly 50–80% in the first six months. Today, lowest-cost generic versions sit at approximately $75–$150 per vial through wholesalers such as Cardinal Health or McKesson, while higher-priced versions still remain at $200–$450.

When did tigecycline generics launch and why did prices drop?

Generic versions launched after Pfizer's exclusivity expired in 2015. The 50 mg vial exclusive rights were challenged and lost in patent litigation. The availability of multiple suppliers—A Accord, Amneal, and Mylan—increased supply and drove the observed price collapse.

What additional costs should hospitals and clinics consider?

Hospitals report extra costs from supply-chain disruptions that sometimes require emergency procurement at premium rates. Extra administrative overhead for managing multiple generic sources and needed sterility assurance tests for injection products also adds expense.

How does tigecycline generic pricing affect patient billing?

Patient billing for tigecycline injection is driven by chargemaster rates rather than acquisition cost. Chargemaster prices often mark up 3–6 times the purchase price, chargemaster rates for 50 mg vials range between $800–$1,500.